Could p53 be a target for therapeutic suppression?

Seminars in Cancer Biology

Volumn 8, Issue 5, 1998, Pages 389-400

  Komarova, Elena A ^b   Gudkov, Andrei V ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

Apoptosis; Chemotherapy; p53; Radiation sensitivity

Indexed keywords

MESSENGER RNA; PROTEIN P53;

APOPTOSIS; CANCER CHEMOTHERAPY; GAMMA IRRADIATION; GROWTH INHIBITION; HEMATOPOIETIC SYSTEM; HUMAN; RADIOSENSITIVITY; REVIEW;

EID: 0000051538     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1998.0101     Document Type: Article

References (92)

1. 1. Gottlieb TM, Oren M (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102
2. 2. Maltzman W, Czyzyk L (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694
3. 3. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6307
4. 4. Tishler RB, Lamppu DM, Park S, Price BD (1995) Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 55:6021-6025
5. 5. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593-602
6. 6. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91
7. 7. Valenzuela MT, Nunez MI, Villalobos M, Siles E, McMillan TJ, Pedraza V, Ruiz de Almodovar JM (1997) A comparison of p53 and p16 expression in human tumor cells treated with hyperthermia or ionizing radiation. Int J Cancer 72:307-312
8. 8. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852
9. 9. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849
10. 10. Canman CE, Gilmer TM, Coutts SB, Kastan MB (1995) Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9:600-611
11. 11. Gottlieb E, Oren M (1998) p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J 17:3587-3596
12. 12. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054-1072
13. 13. Morgan SE, Kastan MB (1997) p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 71:1-25
14. 14. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE (1998) DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394:700-704
15. 15. Canman CE, Kastan MB (1996) Signal transduction. Three paths to stress relief. Nature 384:213-214
16. 16. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
17. 17. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3-11
18. 18. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299
19. 19. Haupt Y, Rowan S, Shaulian E, Kazaz A, Vousden K, Oren M (1997) p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia 3:337-339
20. 20. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723
21. 21. Gu W, Shi XL, Roeder RG (1997) Synergistic activation of transcription by CBP and p53. Nature 387:819-823
22. 22. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827
23. 23. Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov PM, Gudkov AV (1998) The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. Nature 391:295-298
24. 24. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C (1997) Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11:558-570
25. 25. Walton M, Lawlor P, Sirimanne E, Williams C, Gluckman P, Dragunow M (1997) Loss of Ref-1 protein expression precedes DNA fragmentation in apoptotic neurons. Mol Brain Res 44:167-170
26. 26. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299
27. 27. Kubbutat MR, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303
28. 28. Komarova EA, Zelnick CR, Chin D, Zeremski M, Gleiberman AS, Bacus SS, Gudkov AV (1997) Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus. Cancer Res 57:5217-5220
29. 29. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R, Wahl GM (1998) ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 8:145-155
30. 30. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G (1996) Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol 16:1126-1137
31. 31. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS (1992) Bradley Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221
32. 32. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:11-17
33. 33. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935
34. 34. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948
35. 35. Lee JM, Abrahamson JLA, Kandel R, Donehower LA, Bernstein A (1994) Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9:3731-3736
36. 36. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12:3008-3019
37. 37. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12:2434-2442
38. 38. Jacks T (1996) Lessons from the p53 mutant mouse. J Cancer Res Clin Oncol 122:319-327
39. 39. Atadja P, Wong H, Garkavtsev I, Veillette C, Riabowol K (1995) Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci USA 92:8348-8352
40. 40. Harley CB, Sherwood SW (1997) Telomerase, checkpoints and cancer. Cancer Surv 29:263-284
41. 41. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I (1992) Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70:2778-2784
42. 42. Pandrea IV, Mihailovici MS, Carasevici E, Szekely AM, Reynes M, Tarcoveanu E, Dragomir C (1995) An immunohistochemical study of P53 protein on colorectal carcinomas. Rev Med Chir Soc Med Nat lasi 99:171-178
43. 43. Iniesta P, Vega FJ, Caldes T, Massa M, de Juan C, Cerdan FJ, Sanchez A, Lopez JA, Torres AJ, Balibrea JL, Benito M (1998) p53 exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Cancer Lett 130:153-160
44. 44. Norberg T, Jansson T, Sjogren S, Martensson C, Andreasson I, Fjallskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J (1996) Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53. Acta Oncol Suppl 5:96-102
45. 45. Patel DD, Bhatavdekar JM, Chikhlikar PR, Ghosh N, Suthar TP, Shah NG, Mehta RH, Balar DB (1996) Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 62:86-92
46. 46. Fresno M, Molina R, Ferez del Rio MJ, Alvarez S, Diaz-Iglesias JM, Garcia I, Herrero A (1997) p53 expression is of independent predictive value in lymph node-negative breast carcinoma. Eur J Cancer 33:1268-1274
47. 47. Falette N, Paperin MP, Treilleux I, Gratadour AC, Peloux N, Mignotte H, Tooke N, Lofman E, Inganas M, Bremond A, Ozturk M, Puisieux A (1998) Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 58:1451-1455
48. 48. Molina R, Segui MA, Climent MA, Bellmunt J, Albanelll J, Fernandez M, Filella X, Jo J, Gimenez N, Iglesias E, Miralles M, Alonso C, Peiro G, Perez-Picanol E, Ballesta AM (1998) p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res 18:507-511
49. 49. Cordon-Cardo C, Sheinfeld J, Dalbagni G (1997) Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 13:319-327
50. 50. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810
51. 51. Deichman GJ, Matveeva VA, Kashkina LM, Dyakova NA, Uvarova EN, Nikiforov MA, Gudkov AV (1998) Cell transforming genes and tumor progression: in vivo unified secondary phenotypic cell changes. Int J Cancer 75:277-283
52. 52. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584
53. 53. Adolph KW, Liska DJ, Bornstein P (1997) Analysis of the promoter and transcription start sites of the human thrombospondin 2 gene (THBS2). Gene 1915-1911
54. 54. Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF, Bouck N (1995) Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 217:326-332
55. 55. Komarova EA, Diatchenko L, Rokhlin OW, Hill JE, Wang ZJ, Krivokrysenko VI, Feinstein E, Gudkov (1998) Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene 17:1089-1096
56. 56. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE, Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE (1997) Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther 4:675-682
57. 57. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5:931-936
58. 58. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10:175-180
59. 59. Pan H, Griep AE (1995) Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev 9:2157-2169
60. 60. Almog N, Rotter V (1997) Involvement of p53 in cell differentiation and development. Biochim Biophys Acta 13331-13327
61. 61. Shick L, Carman JH, Choi JK, Somasundaram K, Burrell M, Hill DE, Zeng YX, Wang Y, Wiman KG, Salhany K, Kadesch TR, Monroe JG, Donehower LA, el-Deiry WS (1997) Decreased immunoglobulin deposition in tumors and increased immature B cells in p53-null mice. Cell Growth Differ 8:121-131
62. + stage of thymocyte differentiation in the absence of T cell receptor rearrangement. J Exp Med 183:1923-1928
63. 63. Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M (1996) p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 16:5178-5185
64. 64. Schwartz D, Goldfinger N, Rotter V (1993) Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene 8:1487-1494
65. 65. Hendry JH, Adeeko A, Potten CS, Morris ID (1996) p53 deficiency produces fewer regenerating spermatogenic tubules after irradiation. Int J Radiat Biol 70:677-682
66. 66. Wallingford JB, Seufert DW, Virta VC, Vize PD (1997) p53 activity normal development in Xenopus. Curr Biol 7:747-757
67. 67. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, Chin DM, Bacus SS, Stark GR, Gudkov AV (1997) Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16:1391-1400
68. 68. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M (1997) Transgenic mouse model for studying the transcriptional activity of the p53 protein: age-and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 16:1381-1390
69. 69. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A, Walsh FS, Wright EG, Balmain A, Lane DP, Hall PA (1996) The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 13: 2575-2587
70. 70. Hall EJ (1994) Radiology for the radiologist, 4th Edition, J.B. Lippincott Company
71. 71. Kemp CJ, Wheldon T, Balmain A (1994) p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 8:66-69
72. 72. Norimura T, Nomoto S, Katsuki M, Gondo Y, Kondo S (1996) p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nat Med 2:577-580
73. 73. Hall PA, Lane DP (1997) Tumor suppressors: a developing role for p53? Curr Biol 7:144-147
74. 74. Chen X, Ko LJ, Jayaraman L, Prives C (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438-2451
75. 75. Lassus P, Ferlin M, Piette J, Hibner U (1996) Anti-apoptotic activity of low levels of wild-type p53. EMBO J 15:4566-4573
76. 76. Ronen D, Schwartz D, Teitz Y, Goldfinger N, Rotter V (1996) Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Differ 7:21-30
77. 77. Wilson JW, Pritchard DM, Hickman JA, Potten CS (1998) Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and cell cycle arrest. Am J Pathol 153:899-909
78. 78. Rogel A, Popliker M, Webb CG, Oren M (1985) p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5:2851-2855
79. 79. Schmidt P, Lorenz A, Hameister H, Montenarh M (1991) Expression of p53 during mouse embryogenesis. Development 113:857-865
80. 80. Meritt AJ, Potten CS, Kemp W, Hickman JA, Balmain A, Lane DP, Hall PA (1994) The role of p53 in spontaneous and radiation induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54:614-617
81. 81. Cui YF, Zhou PK, Woolford LB, Lord BI, Hendry JH, Wang DW (1995) Apoptosis in bone marrow cells of mice with different p53 genotypes after gamma-rays irradiation in vitro. J Environ Pathol Toxicol Oncol 14:159-163
82. 82. Hasegawa M, Zhang Y, Niibe H, Terry NH, Meistrich ML (1998) Resistance of differentiating spermatogonia to radiation-induced apoptosis and loss in p53-deficient mice. Radiat Res 149:263-270
83. 83. Merritt AJ, Allen TD, Potten CS, Hickman JA (1997) Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene 14:2759-2766
84. 84. Hirabayashi Y, Matsuda M, Matumura T, Mitsui H, Sasaki H, Tukada T, Aizawa S, Yoshida K, Inoue T (1997) The p53-deficient hemopoietic stem cells: their resistance to radiation-apoptosis, but lasted transiently. Leukemia 11 (Suppl 3):489-492
85. 85. Linke SP, Clarkin KC, Wahl GM (1997) p53 mediates permanent arrest over multiple cell cycles in response to γ-irradiation. Cancer Res 57:1171-1179
86. 86. Wlodarski P, Wasik M, Ratajczak MZ, Sevignani C, Hoser G, Kawiak J, Gewirtz AM, Calabretta B, Skorski T (1998) Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood 91:2998-3006
87. 87. Wang L, Cui Y, Lord BI, Roberts SA, Potten CS, Hendry JH, Scott D (1996) Gamma-ray-induced cell killing and chromosome abnormalities in the bone marrow of p53-deficient mice. Radiat Res 146:259-266
88. 88. Hendry JH, Cai WB, Roberts SA, Potten CS (1997) p53 deficiency sensitizes clonogenic cells to irradiation in the large but not the small intestine. Radiat Res 148:254-259
89. 89. Rotter V, Schwartz D, Almon E, Goldfinger N, Kapon A, Meshorer A, Donehower LA, Levine AJ (1993) Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. Proc Natl Acad Sci USA 90:9075-9079
90. 90. Tron VA, Trotter MJ, Tang L, Krajewska M, Reed JC, Ho VC, Li G (1998) p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am J Pathol 153:579-585
91. 91. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y (1998) Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 58:1793-1797
92. 92. Bronchud M (1993) Can hematopoietic growth factors be used to improve the success of cytotoxic chemotherapy? Anticancer Drugs 4:127-139